1.96

2.00% -0.04

After Hours: 1.94 -0.02 -1.02%

Palisade Bio Inc (PALI)

Overview News Price History Financials Discussions Forecast Stock Split

Palisade Bio Inc stock is traded at $1.96, with a volume of 4.12M. It is down -2.00% in the last 24 hours and up +5.95% over the past month. Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.

Previous Close:

$2.00

Open:

$2.03

24h Volume:

4.12M

Relative Volume:

0.93

Market Cap:

$325.53M

Revenue:

$250.00K

Net Income/Loss:

$-16.78M

P/E Ratio:

-1.32

EPS:

-1.4848

Net Cash Flow:

$-10.85M

1W Performance:

-1.51%

1M Performance:

+5.95%

6M Performance:

+118.21%

1Y Performance:

+182.01%

1-Day Range:

$1.92

$2.16

1-Week Range:

$1.83

$2.16

52-Week Range:

$0.53

$2.64

Palisade Bio Inc Stock (PALI) Company Profile

Name

Palisade Bio Inc

Sector

Healthcare (1113)

Industry

Biotechnology (623)

Phone

(858) 704-4900

Address

7750 EL CAMINO REAL, SUITE 5200, CARLSBAD

Employee

Twitter

Next Earnings Date

2026-03-23

Latest SEC Filings

PALI's Discussions on Twitter

Compare PALI vs VRTX, REGN, ALNY, ARGX, INSM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PALI Palisade Bio Inc	1.96	332.17M	250.00K	-16.78M	-10.85M	-1.4848
VRTX Vertex Pharmaceuticals Inc	453.74	115.58B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	756.73	79.23B	14.34B	4.50B	3.77B	41.56
ALNY Alnylam Pharmaceuticals Inc	328.16	43.59B	3.71B	313.75M	465.38M	2.2571
ARGX Argen X Se Adr	692.83	43.26B	4.16B	1.29B	734.26M	19.58
INSM Insmed Inc	147.60	31.97B	606.42M	-1.28B	-997.58M	-6.403

Palisade Bio Inc Stock (PALI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-25-26	Initiated	Stifel	Buy
Jan-09-26	Initiated	B. Riley Securities	Buy
Dec-29-25	Initiated	Piper Sandler	Overweight

Palisade Bio Inc Stock (PALI) Latest News

12:04 PM

Palisade Bio (PALI) reports positive phase 1b data for PALI-2108 in UC patients - MSN

12:04 PM

Mar 24, 2026

Big Picture: Can Palisade Bio Inc expand its profit marginsMarket Performance Summary & Free Accurate Trade Setup Notifications - baoquankhu1.vn

Mar 24, 2026

Mar 23, 2026

PALI SEC FilingsPalisade Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Mar 23, 2026

Palisade Bio: Undervalued Biotech With Blockbuster Potential, Initiating With A Speculative Buy Rating - Seeking Alpha

Mar 23, 2026

Mar 21, 2026

Aug Spikes: Can Palisade Bio Inc expand its profit marginsQuarterly Earnings Report & Weekly Return Optimization Alerts - baoquankhu1.vn

Mar 21, 2026

Mar 20, 2026

Palisade Bio 2026 10-K: Clinical Development, Risk Factors, and Precision Medicine Strategies for IBD - Minichart

Mar 20, 2026

Palisade Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com

Mar 20, 2026

Palisade Bio (NASDAQ:PALI) Issues Quarterly Earnings Results, Beats Estimates By $1.10 EPS - MarketBeat

Mar 20, 2026

Palisade Bio Inc expected to post a loss of 8 cents a shareEarnings Preview - TradingView

Mar 20, 2026

Palisade Bio 10-K: Net loss $16.8M, EPS $(0.30) - TradingView

Mar 20, 2026

[10-K] PALISADE BIO, INC. Files An... - Stock Titan

Mar 20, 2026

Mar 18, 2026

Palisade Bio (PALI) Reports Positive Phase 1b Data for PALI-2108 in UC Patients - Insider Monkey

Mar 18, 2026

PALI Q4'25 Earnings: revenue estimate is 0 USD - TradingView

Mar 18, 2026

Mar 17, 2026

Day Trade: Can Palisade Bio Inc beat the S P 500Bear Alert & Stepwise Trade Execution Plans - baoquankhu1.vn

Mar 17, 2026

Palisade Bio, Inc. (NASDAQ:PALI) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat

Mar 17, 2026

Mar 16, 2026

Palisade Bio (PALI) Expected to Announce Quarterly Earnings on Monday - MarketBeat

Mar 16, 2026

Mar 13, 2026